Mover and shaker

Houston software company hires new CTO after Q1 growth

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

Houston-based Identity Automation has named a new chief technology officer following growth last quarter.

Talin Bingham will replace co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity, according to a release.

"We are excited about the experience and wisdom that Talin brings to this role," says James Litton, CEO at Identity Automation, in the release.

"Talin is a seasoned CTO with an exceptional track record in on-time product delivery and implementation—both of which are essential to the Identity Automation 2.0 growth strategy. We are confident that his entrepreneurial spirit will help us achieve our vision of continued product evolution and rapid expansion across key markets."

Bingham has over 35 years of technical leadership — 25 of which has been in managerial roles. Prior to this appointment, he was the managing director of product and technology at Vista Consulting Group in Utah.

Identity Automation is the provider of RapidIdentity, which is a technology integration platform companies can use to accelerate the digital transformation process. The company has a global presence with tens of millions of identities in its system, which functions both on the premises and cloud resources.

Last summer, the company made its second acquisition — an enterprise single sign-on and virtual desktop platform called HealthCast Inc.

"Identity Automation has the most powerful and scalable platform in the identity management space, backed by a strong leadership team and the momentum of our recent success." Bingham says in the release.

"I'm excited to have a hand in the company's direction during such a pivotal time, ensuring we maximize the quality and delivery of engineering and do so as a cohesive, company-wide effort that make it possible to meet our full potential for growth."

James Litton Discusses Cybersecuritywww.youtube.com

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted